Evidence map›Paper›PMID 41986280›Full record

ArticleBritish journal of haematology2026

Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma.

Yasuyuki Arai, Tomoyasu Jo, Takayuki Sato, Masatoshi Sakurai, Daisuke Kaji, Toshio Kitawaki, Kazuyuki Shimada, Tatsu Shimoyama, Satoshi Yoshihara, Shinichi Makita and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Yasuyuki AraiDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0002-9662-5093
Tomoyasu JoDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID https://orcid.org/0000-0001-9381-0421
Takayuki SatoDepartment of Hematology and Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Masatoshi SakuraiDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Daisuke KajiDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9256-609X
Toshio KitawakiDepartment of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kazuyuki ShimadaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Tatsu ShimoyamaDivision of Clinical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Satoshi YoshiharaDepartment of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan.
Shinichi MakitaDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Nobuharu FujiiDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Go YamamotoDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Keisuke KataokaDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Emiko SakaidaDepartment of Hematology, Chiba University Hospital, Chiba, Japan.
Hideki GotoDepartment of Hematology, Hokkaido University Hospital, Sapporo, Japan.
Yasuhiro NakashimaDepartment of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan.
Akiyo YoshidaDepartment of Hematology, Kanazawa University Hospital, Kanazawa, Japan.
Yoshihiro UmezawaDepartment of Hematology, Institute of Science Tokyo Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1027-1552
Haryoon KimDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Motohiro KatoDepartment of Pediatrics, The University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-5145-1774
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Koji KatoHematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.

Funding

Japan Society for the Promotion of Science 24K19198Ministry of Education, Culture, Sports, Science and Technology
6 · The paper itself

Abstract

Cytokine release syndrome (CRS) remains a major toxicity of chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL), and robust pre-infusion predictors are needed for risk-adapted management. We retrospectively analysed LBCL patients in the Japanese nationwide registry who underwent CD19 CAR-T-cell therapy between 2019 and 2024. Among 900 patients (median age 62 years), cumulative incidences of CRS within 30 days after infusion were 75.0% for any grade, 20.8% for grade ≥ 2 and 14.0% for grade ≥ 3. In multivariable analysis, lower estimated glomerular filtration rate (eGFR) (adjusted hazard ratio [aHR] 1.108 per 10 mL/min per 1.73 m

Indexed as

Cytokine Release SyndromeImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseAdultAgedFemaleGlomerular Filtration RateHumansMaleMiddle AgedRetrospective Studieschimeric antigen receptor T‐cell therapycytokine release syndromeestimated glomerular filtration ratelarge B‐cell lymphoma

Identifiers

PMID41986280
PMCPMC13267435

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.